Identification of PMF1 methylation in association with bladder cancer progression

Clinical Cancer Research

Volumn 14, Issue 24, 2008, Pages 8236-8243

  Aleman, Ainel ^a   Cebrian, Virginia ^a   Alvarez, Miguel ^b   Lopez, Virginia ^a   Orenes, Esteban ^a   Lopez Serra, Lidia ^a   Algaba, Ferran ^c   Bellmunt, Joaquin ^d   Lopez Beltrán, Antonio ^f   Gonzalez Peramato, Pilar ^g   Cordon Cardo, Carlos ^h   García, Javier ⁱ   Muro, Javier Garcíadel ^e   Esteller, Manel ^a   Sánchez Carbayo, Marta ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c FUNDACIÓ PUIGVERT   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^g HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; PMF1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER TUMOR; CANCER CELL; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CPG ISLAND; CYTOPLASM; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; POLYAMINE MODULATED FACTOR 1 GENE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; REGULATOR GENE; TISSUE MICROARRAY; URINALYSIS; DISEASE COURSE; DNA METHYLATION; GENETIC EPIGENESIS; GENETICS; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; HUMANS; MALE; MIDDLE AGED; TRANSCRIPTION FACTORS; URINARY BLADDER NEOPLASMS;

EID: 58149340540     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0778     Document Type: Article

References (30)

1. Cordon-Cardo C, Cote RJ, Sauter G. Genetic and molecular markers of urothelial premalignancy and malignancy. Scand J Urol Nephrol Suppl 2000;205:82-93.
2. Wolff EM, Liang G, Jones PA. Mechanisms of disease: genetic and epigenetic alterations that drive bladder cancer. Nat Clin Pract Urol 2005;2:502-10.
3. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
4. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006;7:21-33.
5. Costello JF, Fruhwald MC, Smiraglia DJ. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000;24:132-8.
6. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002;21:5427 -40.
7. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
8. HuYC, Sidransky D, Ahrendt SA. Molecular detection approaches for smoking associated tumors. Onco-gene 2002;21:7289 -97.
9. Kim WJ, Quan C. Genetic and epigenetic aspects of bladder cancer. J Cell Biochem 2005;95:24-33.
10. Zhang Z, Karam J, Frenkel E, Sagalowsky A, Hsieh JT. The application of epigenetic modifiers on the treatment of prostate and bladder cancer. Urol Oncol 2006;24:152-60.
11. Baffa R, Letko J, McClung C, LeNoir J, Vecchione A, Gomella LG. Molecular genetics of bladder cancer: targets for diagnosis and therapy. J Exp Clin Cancer Res 2006;25:145-60.
12. Gonzalgo ML, Datar RH, Schoenberg MP, Cote RJ. The role of deoxyribonucleic acid methylation in development, diagnosis, and prognosis of bladder cancer. Urol Oncol 2007;25:228-35.
13. 13.Yan PS, Perry MR, LauxDE, et al. CpG island arrays: an application toward deciphering epigenetic signatures of breast cancer. Clin Cancer Res 2000;6:1432-8.
14. Ching TT, Maunakea AK, Jun P, et al. Epigenome analyses using BAC microarrays identify evolutionary conservation of tissue-specific methylation of SHANK3. Nat Genet 2005;37:645 -51.
15. Aleman A, Adrien L, Lopez-Serra L, et al. Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays. BrJ Cancer 2008;98:466 -73.
16. Wang Y, Devereux W, Stewart TM, et al. Cloning and characterization of human polyamine-modulated factor-1, a transcriptional cofactor that regulates the transcription of the spermidine/spermine N(1)-acetyltransferase gene. J Biol Chem 1999;274:22095 -101.
17. 17. Wang Y, Devereux W, Stewart TM, et al. Characterization of the interaction between the transcription factors human polyamine modulated factor (PMF-1) and NF-E2-related factor 2 (Nrf-2) in the transcriptional regulation of the spermidine/spermine N1-acetyl-transferase (SSAT) gene. Biochem J 2001;355:45 -9.
18. WangY, DevereuxW, StewartTM, et al. Polyamine-modulated factor 1 binds to the human homologue of the 7a subunit of the Arabidopsis COP9 signalosome: implications in gene expression. Biochem J 2002;366:79-86.
19. Husbeck B, Stringer DE, Gerner EW, et al. Increased thioredoxin-1 inhibits SSAT expression in MCF-7 human breast cancer cells. Biochem Biophys Res Commun 2003;306:469-75.
20. Wang JY, McCormack SA,Viar MJ, et al. Decreased expression of protooncogenes c-fos, c-myc and c-jun following polyamine depletion in IEC-6 cells. Am J Physiol 1993;265:331 -8.
21. Wang JY, Johnson LR. Expression of protoon-cogenes c-fos and c-myc in healing of gastric mucosal stress ulcers. Am J Physiol 1994;266:878-86.
22. Celano P, Baylin SB, Giardiello FM, et al. Effect of polyamine depletion on c-myc expression in human colon carcinoma cells. J Biol Chem 1988;263:5491 -4.
23. Celano P, Berchtold CM, Giardiello FM, et al. Modulation of growth gene expression by selective alteration of polyamines in human colon carcinoma cells. Biochem Biophys Res Commun 1989;165:384-90.
24. Huang YA, PledgieAA, Casero RA, et al. Molecular mechanisms of polyamine analogs in cancer cells. Anti-Cancer Drugs 2005;16:229-41.
25. Sanchez-Carbayo M, Socci ND, Lozano J, et al. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006;24:778-89.
26. Kirkali Z, ChanT, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66:4-34.
27. Sanchez-Carbayo M, Socci ND, Charytonowicz E, et al. Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res 2002;62:6973 -80.
28. Paz MF, Fraga MF, Avila S, et al. A systematic profile of DNA methylation in human cancer cell lines. Cancer Res 2003;63:1114-21.
29. Dawson-Saunders B,Trapp RG. Basic & clinical bio-statistics. 2nd ed. Norwalk (CT): Appleton & Lange; 1994.
30. Stephenson AH, Seidel ER. Analysis of the interactions of Nrf-2, PMF-1, and CSN-7 with the 5′-flanking sequence of the mouse 4E-BP1 gene. Life Sci 2006; 79:1221 -7.